B1152000

Bromperidol

Name: Bromperidol
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

4-[4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, R 11333

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₂₁H₂₃BrFNO₂

Número CAS:

10457-90-6

Peso molecular:

420.32

NACRES:

NA.24

PubChem Substance ID:

329773171

UNSPSC Code:

41116107

MDL number:

MFCD00866670

Nombre del producto

Bromperidol, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

SMILES string

BrC(C=C1)=CC=C1C(CC2)(O)CCN2CCCC(C3=CC=C(F)C=C3)=O

InChI key

RKLNONIVDFXQRX-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

bromperidol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... DRD2(1813)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Analytical Reference Materials for Pharma QC

Pharmacopeia & Metrological Institute Standards

Application

Bromperidol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Butyrophenone antipsychotic; D₂ dopamine and 5-HT_2A serotonin antagonist.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P301 + P312 + P330

Hazard Classifications

Acute Tox. 4 Oral

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report.

T Suzuki et al.

Journal of clinical pharmacy and therapeutics, 32(5), 525-527 (2007-09-19)

To report the usefulness of antipsychotic dose-reduction for avoiding paralytic ileus in a patient with chronic schizophrenia and comorbid dementia. A 65-year-old in-patient developed severe paralytic ileus warranting a transfer to the general hospital. Constipation was very troublesome and he

Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report.

A Suzuki et al.

European archives of psychiatry and clinical neuroscience, 251(2), 57-59 (2001-06-16)

The relationship between TaqI A dopamine D2 receptor (DRD2) polymorphism and therapeutic response to bromperidol, a selective dopamine antagonist, was investigated in 30 acutely exacerbated schizophrenic inpatients. Patients were treated with bromperidol 6-18 mg/day for 3 weeks. Clinical symptoms were

Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol.

Norio Yasui-Furukori et al.

Therapeutic drug monitoring, 26(3), 336-341 (2004-05-29)

The authors have developed and verified the precision and accuracy of new automated cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol, and cross-validations have been performed with conventional semiautomated EIA kits (MARKIT-M) and high-performance liquid chromatographic (HPLC) methods. The

Lesioning the thalamus for dyskinesia.

C Ohye et al.

Stereotactic and functional neurosurgery, 77(1-4), 33-39 (2002-10-16)

Recent advances on understanding the pallidothalamic relation lead us to perform Vim-Vo thalamotomy (combined thalamic lesion in ventralis intermedius nucleus and ventralis oralis nucleus) for cases with dyskinesia. In our recent series of thalamotomies, there are 12 cases of dyskinesia

Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.

P Benfield et al.

Drugs, 35(6), 670-684 (1988-06-01)

Bromperidol is a close structural analogue of haloperidol. Both agents possess similar pharmacodynamic properties which are consistent with central antidopaminergic activity. The available clinical data from non-comparative and comparative trials have shown that bromperidol possesses antipsychotic activity. Its overall efficacy

Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico